26 related articles for article (PubMed ID: 14670587)
21. Genotypic resistance profile in treatment-experienced HIV-infected individuals after abacavir and efavirenz salvage regimen.
Vallejo A; Olivera M; Rubio A; Sánchez-Quijano A; Lissen E; Leal M
Antiviral Res; 2004 Feb; 61(2):129-32. PubMed ID: 14670587
[TBL] [Abstract][Full Text] [Related]
22. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
23. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
24. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Stürmer M; Staszewski S; Doerr HW
Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
[TBL] [Abstract][Full Text] [Related]
25. Resistance and cross-resistance to abacavir.
Moyle G
HIV Med; 2001 Jul; 2(3):154-62. PubMed ID: 11737395
[TBL] [Abstract][Full Text] [Related]
26. HIV-1 drug resistance: can we overcome?
Brenner BG; Turner D; Wainberg MA
Expert Opin Biol Ther; 2002 Oct; 2(7):751-61. PubMed ID: 12387674
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
